


b.) Amendment to the Claims:

1. (Currently Amended) ~~An antitumor agent which comprises, as an active ingredient, a pyrimidine~~ A pyrimidine derivative represented by Formula (I):

~~[Chemical Formula 15]~~



[wherein

-X-Y-Z- represents -O-CR³=N- {wherein R³ represents a hydrogen atom, hydroxy, carboxy, lower alkyl, lower alkyl substituted with one to four substituents, which may be the same or different and selected from the following substituent group A [substituent group A: halogen, amino, aminosulfonyl, nitro, hydroxy, mercapto, cyano, formyl, carboxy, carbamoyl, lower alkanoyloxy, lower alkanoylamino, mono- or di-(lower alkyl)aminocarbonyl, lower alkoxycarbonyl, mono- or di-(lower alkyl)amino, N-aryl-N-(lower alkyl)amino, lower alkylsulfonyl, lower alkylsulfinyl, mono- or di-(lower alkylsulfonyl)amino, mono- or di-(arylsulfonyl)amino, tri-(lower alkyl)silyl, lower alkylthio, aromatic heterocyclic alkylthio, lower alkanoyl, lower alkanoyl substituted with one to three substituents, which may be the same or different and selected from the following substituent group a (substituent group a: halogen and hydroxy), lower alkoxy, lower alkoxy substituted with one to three substituents, which may be the same or different and selected from the substituent group a, aryloxy, aryloxy substituted with one to three

substituents, which may be the same or different and selected from the substituent group **a**, aralkyloxy, and aralkyloxy substituted with one to three substituents, which may be the same or different and selected from the substituent group **a**; wherein, when the substituted lower alkyl is substituted methyl, substituted ethyl, or substituted propyl, the substituent may be $-NR^4R^5$ (wherein R^4 and R^5 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted heteroalicyclic group)], substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkylthio, substituted or unsubstituted lower alkanoyl, or $-C(=O)NR^6R^7$ (wherein R^6 and R^7 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted heteroalicyclic group, or R^6 and R^7 are combined together with

the adjacent nitrogen atom thereto to form a substituted or unsubstituted heteroalicyclic group)), -N=CR^{3a}-O- (wherein R^{3a} has the same definition as R³ described above), -O-N=CR^{3b}- (wherein R^{3b} has the same definition as R³ described above), -O-C(=O)-NR⁸- (wherein R⁸ represents a hydrogen atom, lower alkyl, lower alkyl substituted with one to four substituents, which may be the same or different and selected from the substituent group A, or substituted or unsubstituted heteroalicyclic alkyl), -N=N-NR⁹- (wherein R⁹ represents substituted or unsubstituted lower alkyl or substituted or unsubstituted heteroalicyclic alkyl), or -NR^{9a}-N=N- (wherein R^{9a} has the same definition as R⁹ described above);

R¹ represents -NR¹⁰R¹¹ (wherein R¹⁰ and R¹¹ may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted monocyclic aryl, a substituted or unsubstituted aromatic monoheterocyclic group, or a substituted or unsubstituted heteroalicyclic group, or R¹⁰ and R¹¹ are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heteroalicyclic group; wherein, when one of R¹⁰ and R¹¹ is a hydrogen atom, the other of R¹⁰ and R¹¹ is not a group selected from substituted or unsubstituted pyrazol-3-yl and substituted or unsubstituted 1,2,4-triazol-3-yl), or -OR¹² (wherein R¹² represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted

or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted heteroalicyclic group); and

R^2 represents $-NR^{13}R^{14}$ (wherein R^{13} and R^{14} may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted monocyclic aryl, a substituted or unsubstituted aromatic monoheterocyclic group, or a substituted or unsubstituted heteroalicyclic group, or R^{13} and R^{14} are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heteroalicyclic group or a substituted or unsubstituted aromatic heterocyclic group; wherein R^{13} and R^{14} do not simultaneously represent a hydrogen atom, and when one of R^{13} and R^{14} is a hydrogen atom, the other of R^{13} and R^{14} is not substituted or unsubstituted pyrazol-3-yl)]


or a pharmaceutically acceptable salt thereof.

2. (Currently Amended) ~~The antitumor~~ An antitumor agent comprising the pyrimidine derivative or pharmaceutically acceptable salt thereof according to Claim 1 together with a pharmaceutically acceptable carrier, wherein the tumor is a hematopoietic tumor.

3. (Currently Amended) A therapeutic agent for leukemia, ~~which comprises, as an active ingredient,~~ comprising the pyrimidine derivative or the pharmaceutically acceptable salt thereof described in Claim 1 together with a pharmaceutically acceptable carrier.

4. (Currently Amended) A pyrimidine derivative represented by Formula (IA):

~~[Chemical Formula 16]~~



~~[wherein -X-Y-Z- and R¹ have the same definitions as described above, respectively;~~

-X-Y-Z- represents -O-CR³=N- {wherein R³ represents a hydrogen atom, hydroxy, carboxy, lower alkyl, lower alkyl substituted with one to four substituents, which may be the same or different and selected from the following substituent group A
[substituent group A: halogen, amino, aminosulfonyl, nitro, hydroxy, mercapto, cyano, formyl, carboxy, carbamoyl, lower alkanoyloxy, lower alkanoylamino, mono- or di-(lower alkyl)aminocarbonyl, lower alkoxycarbonyl, mono- or di-(lower alkyl)amino, N-aryl-N-(lower alkyl)amino, lower alkylsulfonyl, lower alkylsulfinyl, mono- or di-(lower alkylsulfonyl)amino, mono- or di-(arylsulfonyl)amino, tri-(lower alkyl)silyl, lower alkylthio, aromatic heterocyclic alkylthio, lower alkanoyl, lower alkanoyl substituted with

one to three substituents, which may be the same or different and selected from the
following substituent group a (substituent group a: halogen and hydroxy), lower alkoxy,
lower alkoxy substituted with one to three substituents, which may be the same or different
and selected from the substituent group a, aryloxy, aryloxy substituted with one to three
substituents, which may be the same or different and selected from the substituent group a,
aralkyloxy, and aralkyloxy substituted with one to three substituents, which may be the
same or different and selected from the substituent group a; wherein, when the substituted
lower alkyl is substituted methyl, substituted ethyl, or substituted propyl, the substituent
may be -NR⁴R⁵ (wherein R⁴ and R⁵ may be the same or different, and each represents a
hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower
alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl,
substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted
heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted
aromatic heterocyclic group, or a substituted or unsubstituted heteroalicyclic group)],
substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl,
substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic
alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a
substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted
heteroalicyclic group, substituted or unsubstituted lower alkoxy, substituted or
unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkylthio,
substituted or unsubstituted lower alkanoyl, or -C(=O)NR⁶R⁷ (wherein R⁶ and R⁷ may be
the same or different, and each represents a hydrogen atom, substituted or unsubstituted
lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower

alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted heteroalicyclic group, or R⁶ and R⁷ are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heteroalicyclic group)}, -N=CR^{3a}-O- (wherein R^{3a} has the same definition as R³ described above), -O-N=CR^{3b}- (wherein R^{3b} has the same definition as R³ described above), -O-C(=O)-NR⁸- (wherein R⁸ represents a hydrogen atom, lower alkyl, lower alkyl substituted with one to four substituents, which may be the same or different and selected from the substituent group A, or substituted or unsubstituted heteroalicyclic alkyl), -N=N-NR⁹- (wherein R⁹ represents substituted or unsubstituted lower alkyl or substituted or unsubstituted heteroalicyclic alkyl), or -NR^{9a}-N=N- (wherein R^{9a} has the same definition as R⁹ described above);

R¹ represents -NR¹⁰R¹¹ (wherein R¹⁰ and R¹¹ may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted monocyclic aryl, a substituted or unsubstituted aromatic monoheterocyclic group, or a substituted or unsubstituted heteroalicyclic group, or R¹⁰ and R¹¹ are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heteroalicyclic group; wherein, when one of R¹⁰ and R¹¹ is a hydrogen atom, the other of R¹⁰ and R¹¹ is not a

group selected from substituted or unsubstituted pyrazol-3-yl and substituted or unsubstituted 1,2,4-triazol-3-yl), or -OR¹² (wherein R¹² represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted heteroalicyclic group); and

R^{2A} represents -NR^{13A}R^{14A} {wherein R^{13A} and R^{14A} may be the same or different, and each represents a hydrogen atom, lower alkyl, lower alkyl substituted with one to four substituents, which may be the same or different and selected from the following substituent group B [substituent group B: halogen, amino, aminosulfonyl, nitro, hydroxy, mercapto, cyano, formyl, carboxy, carbamoyl, lower alkanoyloxy, lower alkanoylamino, mono- or di-(lower alkyl)aminocarbonyl, lower alkoxycarbonyl, mono- or di-(lower alkyl)amino, N-aryl-N-(lower alkyl)amino, lower alkylsulfonyl, lower alkylsulfinyl, mono- or di-(lower alkylsulfonyl)amino, mono- or di-(arylsulfonyl)amino, tri-(lower alkyl)silyl, lower alkylthio, aromatic heterocyclic alkylthio, lower alkanoyl, lower alkanoyl substituted with one to three substituents, which may be the same or different and selected from the following substituent group a (substituent group a: halogen and hydroxy), lower alkoxy, lower alkoxy substituted with one to three substituents, which may be the same or different and selected from the substituent group a, aryloxy, aryloxy substituted with one to three substituents, which may be the same or different and selected from the substituent group a, aralkyloxy, and aralkyloxy substituted with one to three substituents, which may be the same or different and selected from the substituent group

a], substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted monocyclic aryl, or a substituted or unsubstituted heteroalicyclic group, or R^{13A} and R^{14A} are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heteroalicyclic group or a substituted or unsubstituted aromatic heterocyclic group, wherein R^{13A} and R^{14A} do not simultaneously represent a hydrogen atom}, -NR¹⁵CR^{16A}R^{16B}-Ar {wherein R¹⁵ represents a hydrogen atom or lower alkyl; R^{16A} and R^{16B} may be the same or different, and each represents a hydrogen atom, lower alkyl, or lower alkyl substituted with one to three substituents, which may be the same or different and selected from the following substituent group **b** (substituent group **b**: halogen, hydroxy, and hydroxymethyl); and Ar represents aryl, aryl substituted with one to three substituents, which may be the same or different and selected from the following substituent ~~group C~~ [~~substituent group C~~ group c [substituent group c: halogen, amino, nitro, hydroxy, mercapto, cyano, carboxy, aminosulfonyl, lower alkyl, lower alkyl substituted with one to three substituents, which may be the same or different and selected from the substituent group **b**, lower alkoxy, lower alkylthio, mono- or di-(lower alkyl)amino, lower alkanoylamino, mono- or di-(lower alkylsulfonyl)amino, lower alkoxy-carbonylamino, heteroalicyclic alkyloxy, and alkylenedioxy], an aromatic heterocyclic group, or an aromatic heterocyclic group substituted with one to three substituents, which may be the same or different and selected from the substituent ~~group C~~ group c], or -NR¹⁵CR^{16A}R^{16B}CR^{17A}R^{17B}-Ar (wherein R¹⁵, R^{16A}, R^{16B}, and Ar have the same definitions as described above, respectively; and R^{17A} and R^{17B} have the same definition as R^{16A} and R^{16B} described above, respectively)]

or a pharmaceutically acceptable salt thereof.

5. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 4, wherein -X-Y-Z- is -O-CR³=N- (wherein R³ ~~has the same definition as described above~~ represents a hydrogen atom, hydroxy, carboxy, lower alkyl, lower alkyl substituted with one to four substituents, which may be the same or different and selected from the following substituent group A [substituent group A: halogen, amino, aminosulfonyl, nitro, hydroxy, mercapto, cyano, formyl, carboxy, carbamoyl, lower alkanoyloxy, lower alkanoylamino, mono- or di-(lower alkyl)aminocarbonyl, lower alkoxycarbonyl, mono- or di-(lower alkyl)amino, N-aryl-N-(lower alkyl)amino, lower alkylsulfonyl, lower alkylsulfinyl, mono- or di-(lower alkylsulfonyl)amino, mono- or di-(arylsulfonyl)amino, tri-(lower alkyl)silyl, lower alkylthio, aromatic heterocyclic alkylthio, lower alkanoyl, lower alkanoyl substituted with one to three substituents, which may be the same or different and selected from the following substituent group a (substituent group a: halogen and hydroxy), lower alkoxy, lower alkoxy substituted with one to three substituents, which may be the same or different and selected from the substituent group a, aryloxy, aryloxy substituted with one to three substituents, which may be the same or different and selected from the substituent group a, aralkyloxy, and aralkyloxy substituted with one to three substituents, which may be the same or different and selected from the substituent group a; wherein, when the substituted lower alkyl is substituted methyl, substituted ethyl, or substituted propyl, the substituent may be -NR⁴R⁵ (wherein R⁴ and R⁵ may be the same or different, and each represents a

hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted heteroalicyclic group)], substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted heteroalicyclic group, substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted lower alkylthio, substituted or unsubstituted lower alkanoyl, or -C(=O)NR⁶R⁷ (wherein R⁶ and R⁷ may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aromatic heterocyclic alkyl, substituted or unsubstituted heteroalicyclic alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted heteroalicyclic group, or R⁶ and R⁷ are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heteroalicyclic group)).

6. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 4, wherein -X-Y-Z- is -O-CR^{3A}=N- (wherein R^{3A} represents lower alkyl, lower alkyl substituted with one to four substituents, which may be the same or different and selected from the substituent ~~group A~~ group a, or heteroalicyclic alkyl).

7. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claims 5 to 6, wherein R¹ is -NR¹⁰R¹¹ (~~wherein R¹⁰ and R¹¹ have the same definitions as described above, respectively~~), and R^{2A} is ~~-NR¹⁵CR^{16A}R^{16B}-Ar (wherein R¹⁵, R^{16A}, R^{16B}, and Ar have the same definitions as described above, respectively) or -NR¹⁵CR^{16A}R^{16B}CR^{17A}R^{17B}-Ar (wherein R¹⁵, R^{16A}, R^{16B}, R^{17A}, R^{17B}, and Ar have the same definitions as described above, respectively)~~.

8. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to ~~any of Claims 5 to 7~~ Claim 7, wherein R¹ is -NHR^{10A} (wherein R^{10A} represents substituted or unsubstituted lower alkyl or substituted or unsubstituted monocyclic aryl).

9. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to ~~any of Claims 5 to 8~~ Claim 8, wherein R^{2A} is $-\text{NH}(\text{CH}_2)_2-\text{Ar}$ (~~wherein Ar has the same definition as described above~~).

10. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to ~~any of Claims 5 to 8~~ Claim 8, wherein R^{2A} is $-\text{NH}(\text{CH}_2)_2-\text{Ar}^1$ (wherein Ar^1 represents phenyl or phenyl substituted with one to three substituents, which may be the same or different and selected from the substituent ~~group c~~ group c).

11. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to ~~any of Claims 5 to 8~~ Claim 8, wherein R^{2A} is $-\text{NH}(\text{CH}_2)_2-\text{Ar}^2$ (wherein Ar^2 represents pyridyl or pyridyl substituted with one to three substituents, which may be the same or different and selected from the substituent ~~group c~~ group c).


12. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 4, wherein $-\text{X}-\text{Y}-\text{Z}-$ is $-\text{O}-\text{C}(=\text{O})-\text{NR}^8-$ (~~wherein R^8 has the same definition as described above~~).

13. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 12, wherein R^1 is $-NR^{10}R^{11}$ ~~(wherein R^{10} and R^{11} have the same definitions as described above, respectively)~~, and R^{2A} is $-NR^{15}CR^{16A}R^{16B}-Ar$ ~~(wherein R^{15} , R^{16A} , R^{16B} , and Ar have the same definitions as described above, respectively)~~ or $-NR^{15}CR^{16A}R^{16B}CR^{17A}R^{17B}-Ar$ ~~(wherein R^{15} , R^{16A} , R^{16B} , R^{17A} , R^{17B} , and Ar have the same definitions as described above, respectively)~~.

14. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 12, wherein R^1 is $-NHR^{10B}$ (wherein R^{10B} represents substituted or unsubstituted lower alkyl), and R^{2A} is $-NH(CH_2)_2-Ar$ ~~(wherein Ar has the same definition as described above)~~.

15. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to any of Claims 12 to 14, wherein R^{2A} is

~~[Chemical Formula 17]~~




16. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 4, wherein -X-Y-Z- is -N=N-NR⁹- ~~(wherein R⁹ has the same definition as described above)~~ or -NR^{9a}-N=N- ~~(wherein R^{9a} has the same definition as described above)~~.

17. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 16, wherein R¹ is -NR¹⁰R¹¹ ~~(wherein R¹⁰ and R¹¹ have the same definitions as described above, respectively)~~, and R^{2A} is -NR¹⁵(CH₂)_n-Ar ~~(wherein R¹⁵ and Ar have the same definitions as described above, respectively; and n represents 1 or 2)~~.

18. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 16, wherein R¹ is -NHR^{10B} ~~(wherein R^{10B} has the same definition as described above)~~, and R^{2A} is -NH(CH₂)₂-Ar ~~(wherein Ar has the same definition as described above)~~.

19. (Currently Amended) The pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 16, wherein R¹ is -NHR^{10B} ~~(wherein R^{10B} has the same definition as described above)~~, and R^{2A} is

[Chemical Formula 18]



20. (Currently Amended) A pharmaceutical composition which comprises, as an active ingredient, the pyrimidine derivative or the pharmaceutically acceptable salt thereof according to ~~any of Claims 4 to 19~~ Claim 15 together with a pharmaceutically acceptable carrier.

21. (Currently Amended) An antitumor agent which comprises, as an active ingredient, the pyrimidine derivative or the pharmaceutically acceptable salt thereof according to ~~any of Claims 4 to 19~~ Claims 16 to 19 together with a pharmaceutically acceptable carrier.

22. (Original) The antitumor agent according to Claim 21, wherein the tumor is a hematopoietic tumor.

23. (Currently Amended) A therapeutic agent for leukemia, which comprises, as an active ingredient, the pyrimidine derivative or the pharmaceutically

acceptable salt thereof according to ~~any of Claims 4 to 19~~ Claim 15 together with a pharmaceutically acceptable carrier.

24. (Currently Amended) A method for treating a tumor, which comprises a step of administering an effective amount of the pyrimidine derivative or the pharmaceutically acceptable salt thereof according to Claim 1 to a patient in need thereof.

Claims 25-26 (Cancelled).

27. (Currently Amended) A method for treating a tumor, which comprises a step of administering an effective amount of the pyrimidine derivative or the pharmaceutically acceptable salt thereof according to ~~any of Claims 4 to 19~~ Claim 15 to a patient in need thereof.

28. (Currently Amended) A method for treating a hematopoietic tumor, which comprises a step of administering an effective amount of the pyrimidine derivative or the pharmaceutically acceptable salt thereof according to any of ~~Claims 4 to 19~~ Claims 16 to 19 to a patient in need thereof.

29. (Currently Amended) A method for treating leukemia, which comprises a step of administering an effective amount of the pyrimidine derivative or the pharmaceutically acceptable salt thereof according to any of ~~Claims 4 to 19~~ Claims 16 to 19 to a patient in need thereof.

Claims 30-35 (Cancelled).